Alnylam Pharmaceuticals · 4 hours ago
Business Account Executive, Rare Disease -South Florida (Miami, West Palm Beach, Ft. Lauderdale)
United States
Full-time
Remote
Senior Level
$144K/yr - $196K/yr
5+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, focusing on transforming the lives of patients with rare diseases. They are seeking an experienced Business Account Executive to drive physician and patient identification, disease awareness, and brand awareness within the South Florida territory.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Responsibilities
Drive patient identification through appropriate HCP driven strategies including market development, increase brand awareness through building and executing a territory strategy/account plan; continuously assess opportunities within markets and accounts to launch successfully
Effectively prioritize and manage time, activities, and resources in order to optimize access to academic and community HCPs
Build and maintain relationships with HCPs and office staff by maximizing their time through planning, leveraging insights, and conducting post-call analysis refining tactics based on opportunities
Proactively build effective working relationships with internal/external stakeholders; drive agreement/decisions from multiple stakeholders; demonstrated high level of emotional intelligence adapting communication based on different stakeholders
Collaborate with stakeholders across all commercial departments including; patient services, field reimbursement, and others to ensure access at site of care and that logistics are in place to administer medications
Collaborate with key accounts and physicians to build individual account plans to drive patient identification through market development and physician education; achieve sales goals, and maintain relationships in order to maximize sales results
Execute speaker programs, local sponsorships, displays and exhibits, both in and out of office across multiple account types: academic institutions, physician offices, infusion centers, and alternate site locations
Routinely report territory-level market dynamics and trends, including prescriber opinion and competitive activity to RBD as required
Qualification
Required
Bachelor's degree required
5+ years of demonstrated success in biotech, specialty pharmaceuticals, or medical devices
Thorough understanding of site of care identification, development and education
Strong examples of applied entrepreneurial mindset, business analytics and data analysis required
Must be familiar with relevant legal and regulatory environment in biotech/pharmaceutical industry
Strong communication and listening skills
Effective at managing complex individualized cases in a compliant manner
Overnight travel required including travel to Boston, congresses and large geographical territories
Candidates must have a valid driver's license
Must live in the assigned territory
Preferred
Experience, success and relationships in Rare Disease, Gastroenterology, Hepatology, Neurology, Hematology/Oncology, pediatric and adult Nephrology and/or Urology are preferred but not required
Buy & Bill understanding and experience working with HUB patient services preferred but not required
Experience supporting biologic therapy administered by designated HCPs preferred
Experience driving, leading and delivering upon territory-level cross functional business planning
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
Lifestyle reimbursement program
Flexible spending and health savings accounts
401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Clinical Trials Arena
2026-01-16
Longevity.Technology
2026-01-14
2026-01-13
Company data provided by crunchbase